Page last updated: 2024-10-30

mecamylamine and Autosomal Dominant Juvenile Parkinson Disease

mecamylamine has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 2 studies

Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Stuckenholz, V1
Bacher, M1
Balzer-Geldsetzer, M1
Alvarez-Fischer, D1
Oertel, WH1
Dodel, RC1
Noelker, C1
Yanagida, T1
Takeuchi, H1
Kitamura, Y1
Takata, K1
Minamino, H1
Shibaike, T1
Tsushima, J1
Kishimoto, K1
Yasui, H1
Taniguchi, T1
Shimohama, S1

Other Studies

2 other studies available for mecamylamine and Autosomal Dominant Juvenile Parkinson Disease

ArticleYear
The α7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice.
    Journal of Parkinson's disease, 2013, Volume: 3, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzamides; Bridged Bicyclo Compounds; Calcium-Binding Prot

2013
Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model.
    Neuroscience research, 2008, Volume: 62, Issue:4

    Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Disease Models, Animal; Dopamine Uptake Inhibitors

2008